Paper24980665
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Ferdinand KC and 9 others. Hypertension, 2014. Cited by 123 papers, by iCite.
Cite this record
ConductScience Library. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Papers, record 24980665. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24980665
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Blood Pressure | Major topic |
| Diabetes Mellitus, Type 2 | Major topic |
| Glucagon-Like Peptides | Major topic |
| Heart Rate | Major topic |
| Immunoglobulin Fc Fragments | Major topic |
| Receptors, Glucagon | Major topic |
| Recombinant Fusion Proteins | Major topic |
| Aged | |
| Blood Pressure Monitoring, Ambulatory | |
| Diarrhea | |
| Double-Blind Method | |
| Drug Administration Schedule | |
| Female | |
| Glucagon-Like Peptide-1 Receptor | |
| Glycated Hemoglobin | |
| Humans | |
| Hypoglycemic Agents | |
| Injections, Subcutaneous | |
| Male | |
| Middle Aged | |
| Nausea | |
| Treatment Outcome | |
| Vomiting |
Source PubMed
Cited by72
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42830469 | Glucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications. | Pharmacol Res Perspect | 2026 | https://conductscience.org/library/papers/42830469 | PubMed |
| 42750018 | Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis. | BMC Endocr Disord | 2026 | https://conductscience.org/library/papers/42750018 | PubMed |
| 42719822 | GLP-1 receptor agonists in cardiovascular disease: a guide for cardiologists. | Br J Cardiol | 2026 | https://conductscience.org/library/papers/42719822 | PubMed |
| 42380521 | Contractile effects of dulaglutide in the human atrium. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42380521 | PubMed |
| 42365335 | Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials. | Diabetol Metab Syndr | 2026 | https://conductscience.org/library/papers/42365335 | PubMed |
| 42076099 | Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42076099 | PubMed |
| 41489846 | Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials. | Endocrine | 2026 | https://conductscience.org/library/papers/41489846 | PubMed |
| 41425685 | New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report. | Cureus | 2025 | https://conductscience.org/library/papers/41425685 | PubMed |
| 41378487 | Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction. | J Am Heart Assoc | 2025 | https://conductscience.org/library/papers/41378487 | PubMed |
| 41324724 | Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists. | Curr Hypertens Rep | 2025 | https://conductscience.org/library/papers/41324724 | PubMed |
| 41102420 | Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight. | Hypertens Res | 2025 | https://conductscience.org/library/papers/41102420 | PubMed |
| 41050409 | Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41050409 | PubMed |
| 40458885 | Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. | Future Cardiol | 2025 | https://conductscience.org/library/papers/40458885 | PubMed |
| 40214900 | Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis. | Diabetes Ther | 2025 | https://conductscience.org/library/papers/40214900 | PubMed |
| 39954057 | Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study. | Acta Diabetol | 2025 | https://conductscience.org/library/papers/39954057 | PubMed |
| 39217384 | The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension. | Clin Hypertens | 2024 | https://conductscience.org/library/papers/39217384 | PubMed |
| 39145614 | GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. | J Endocrinol | 2024 | https://conductscience.org/library/papers/39145614 | PubMed |
| 39071115 | Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor. | Ther Adv Endocrinol Metab | 2024 | https://conductscience.org/library/papers/39071115 | PubMed |
| 38983582 | The Global Burden of Resistant Hypertension and Potential Treatment Options. | Eur Cardiol | 2024 | https://conductscience.org/library/papers/38983582 | PubMed |
| 38766425 | Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth? | World J Diabetes | 2024 | https://conductscience.org/library/papers/38766425 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24980665
GET https://conductscience.org/api/papers/v1/24980665/cited_by?page=2